| Company founded with
name “Zymos” |
1981 |
| Collaboration with Novo Nordisk
to develop recombinant human insulin |
1982 |
| Company name changed to ZymoGenetics |
1983 |
| Cloning of human Factor VII |
1986 |
| ZymoGenetics acquired by Novo Nordisk |
1988 |
| Recombinant human Insulin (Novolin®)
marketed by Novo Nordisk (manufacturing
process developed by ZymoGenetics) |
1988 |
| PDGF-BB - First product that ZymoGenetics
takes into clinical studies |
1991 |
| Moved into historic Seattle City
Light Lake Union Steam Plant |
1994 |
| First to clone Thrombopoietin (Voted
“Discovery of the Decade” by Discover
Magazine) |
1994 |
| Established bioinformatics-driven
discovery research program |
1994 |
| Factor VIIa (NovoSeven®) marketed
by Novo Nordisk (licensed from ZymoGenetics) |
1996 |
| PDGF-BB (Regranex®) marketed
by J&J (licensed from ZymoGenetics) |
1997 |
| TPA analog (Cleactor™)
marketed by Eisai (licensed from ZymoGenetics) |
1998 |
| ZymoGenetics re-established as independent
company |
2000 |
| Established License & Option Agreement
with Novo Nordisk |
2000 |
| George Rathmann elected Chairman
of the Board of Directors |
2000 |
| Established co-development partnership
for atacicept with Serono S.A. |
2001 |
| Completed Initial Public Offering |
2002 |
| Sold corporate headquarters raising
$52M in sale/leaseback transaction |
2002 |
| Filed and settled patent infringement
lawsuit with Amgen/Immunex Corp. over
Enbrel® |
2002 |
| Initiated clinical trials with atacicept
and RECOTHROM™ Thrombin, topical (Recombinant) |
2003 |
| Started clinical development of
IL-21 |
2004 |
Opened Earl Davie Building II with
clinical manufacturing facility
|
2004 |
| Entered into broad strategic alliance
with Serono |
2004 |
| Designated PEG-interferon lambda (IL-29) as fourth product
candidate |
2005 |
| ZymoGenetics celebrated 25 years of innovation |
2006 |
| Completed RECOTHROM Phase 3 clinical trial and filed rThrombin BLA |
2006 |
| Established RECOTHROM collaboration with Bayer HealthCare |
2007 |
| FDA approved RECOTHROM, marketed by ZymoGenetics and Bayer |
2008 |
Back to top
